Abstract
8-12% of mCRC patients harbour a BRAFV600E mutation (BRAFMT), which confers a poor prognosis. In the first-line setting, there is no specific treatment for BRAFMT-mCRC, although a doublet or triplet chemotherapy (CT) plus bevacizumab is recommended by European guidelines. CAPSTAN is a retrospective, multicentre, observational study to describe effectiveness and safety of first-line regimens in BRAF MT mCRC patients in Europe.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
